Home > Pressemitteilung: Würzburg Researchers Discover a Novel ...

Thrombo-inflammation is a dangerous condition where blood clotting and inflammation occur simultaneously, overwhelming the ...

I saw a transformation in the appearance of my dark circles, clearer skin generally, and faster healing of post-blemish ...

More than half of patients in a Phase III clinical trial who received a limited course of the experimental monoclonal ...

Chronic liver disease gets worse when the liver's immune system stays overactive, resulting in ongoing inflammation and ...

Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing transformative therapeutics to overcome the limitations of current anticoagulation therapy, today highlighted the ...

Depression is not only a disorder of mood but also a condition that affects the heart and blood vessels, and can carry ...

China: A recent study published in Medicine highlights the clinical value of combining plasma D-dimer testing, color Doppler ...

On November 2, 2025, the research group led by Dr. Zeng Ling from Army Medical University systematically elucidated the molecular mechanisms, ...

INTENT Biologics, a clinical-stage biotechnology company developing PEP Biologic as the first-in-class exosome-based biologic therapies for serious conditions with significant unmet medical need, ...

The company outlined progress on its anticoagulation pipeline, including its HIT program VLX-1005, at a Lytham Partners ...